1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Cardiovascular Devices Market Trends
  5. > Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015

Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015

Summary

GlobalData's Medical Devices sector report, “Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015" provides an overview of Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB) products currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) products under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) products and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) products under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloons (DEB) Overview 5
3 Products under Development 6
3.1 PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 6
3.2 PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Territory 7
3.3 PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 8
3.4 PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 9
3.5 PTCA Coronary Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 10
4 PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies 11
4.1 PTCA Coronary Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 11
4.2 PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 12
5 PTCA Coronary Drug Eluting Balloons (DEB) Companies and Product Overview 13
5.1 Acrostak (Schweiz) AG Company Overview 13
5.1.1 Acrostak (Schweiz) AG Pipeline Products and Ongoing Clinical Trials Overview 13
5.2 B. Braun Melsungen AG Company Overview 15
5.2.1 B. Braun Melsungen AG Pipeline Products and Ongoing Clinical Trials Overview 15
5.3 Concept Medical Inc Company Overview 24
5.3.1 Concept Medical Inc Pipeline Products and Ongoing Clinical Trials Overview 24
5.4 Eurocor GmbH Company Overview 27
5.4.1 Eurocor GmbH Pipeline Products and Ongoing Clinical Trials Overview 27
5.5 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview 29
5.5.1 Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products and Ongoing Clinical Trials Overview 29
5.6 Maxcor Inc. Company Overview 30
5.6.1 Maxcor Inc. Pipeline Products and Ongoing Clinical Trials Overview 30
5.7 Micell Technologies, Inc. Company Overview 31
5.7.1 Micell Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 31
5.8 QualiMed Innovative Medizinprodukte GmbH Company Overview 33
5.8.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products and Ongoing Clinical Trials Overview 33
5.9 The Spectranetics Corporation Company Overview 35
5.9.1 The Spectranetics Corporation Pipeline Products and Ongoing Clinical Trials Overview 35
5.10 Vascular Nanotransfer Technologies Company Overview 37
5.10.1 Vascular Nanotransfer Technologies Pipeline Products and Ongoing Clinical Trials Overview 37
6 PTCA Coronary Drug Eluting Balloons (DEB)- Recent Developments 39
7 Appendix 45
7.1 Methodology 45
7.2 About GlobalData 47
7.3 Contact Us 48
7.4 Disclaimer 48

1.1 List of Tables
Table 1: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 6
Table 2: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Territory 7
Table 3: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 8
Table 4: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 9
Table 5: PTCA Coronary Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 10
Table 6: PTCA Coronary Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 11
Table 7: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 12
Table 8: Acrostak (Schweiz) AG Pipeline Products and Ongoing Clinical Trials Overview 13
Table 9: Genie Catheter - Product Status 14
Table 10: Genie Catheter - Product Description 14
Table 11: B. Braun Melsungen AG Pipeline Products and Ongoing Clinical Trials Overview 15
Table 12: SeQuent Please - Product Status 16
Table 13: SeQuent Please - Product Description 16
Table 14: B. Braun Melsungen AG - Ongoing Clinical Trials Overview 17
Table 15: SeQuent Please - A Prospective Randomized Multicenter Non-inferiority Clinical Study to Determine the Safety and Performance of the Agent Paclitaxel-coated PTCA Balloon Catheter (Hemoteq) Compared to the SeQuent Please Paclitaxel-releasing Coronary Balloon Catheter (B.Braun) for the Treatment of Coronary In-stent Restenosis (AGENT-ISR) 19
Table 16: SeQuent Please - A Prospective, Randomized, Controlled, Open Label, Multicenter Trial to Test the Non-inferiority of Drug Eluting Balloon Versus Drug Eluting Stent Treatment in de Novo Stenoses of Small Native Vessels Regarding Efficacy and Safety 19
Table 17: SeQuent Please - Absorb Bioresorbable Scaffold Vs. Drug Coated Balloon for Treatment of In-stent-restenosis 20
Table 18: SeQuent Please - Bare Metal Stent Versus Drug Coated Balloon with Provisional Stenting in Non-ST-Elevation Myocardial Infarction 20
Table 19: SeQuent Please - Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms: a Multi-modality, Multi-specialty Collaborative Study (PERFECT Program) 21
Table 20: SeQuent Please - DARE-Trial: Drug Eluting bAlloon for In-stent REstenosis. Multi-center, Randomized Trial to Study the Effect of the SeQuent Please Drug-eluting Balloon Versus the Xience Prime Drug-eluting Stent for the Treatment of In-stent Restenosis 21
Table 21: SeQuent Please - Drug-Eluting Balloon in Stable and Unstable Angina: A Randomized Controlled Non-inferiority Trial 22
Table 22: SeQuent Please - Effect of Combination of Non-slip Element Balloon (NSE) and Drug-coated Balloon (DCB) for In-stent Restenosis Lesions (ELEGANT) 22
Table 23: SeQuent Please - Randomized Controlled Trial of Drug Coated Balloon Compared to Bare Metal Stent Using FFR-guidance for the Treatment of de Novo Coronary Artery Lesions 22
Table 24: SeQuent Please - The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) 23
Table 25: SeQuent Please - Treatment of Drug-Eluting Stent Restenosis Using Drug-Eluting Stents vs. Drug-Coated Balloon for Preventing Recurrent In-Stent Restenosis 23
Table 26: SeQuent Please - Trial of a Novel Paclitaxel-coated Balloon with Citrate Excipient for Restenosis in -Limus Analogue Drug-eluting Coronary Stents 23
Table 27: Concept Medical Inc Pipeline Products and Ongoing Clinical Trials Overview 24
Table 28: Magic Touch - Product Status 24
Table 29: Magic Touch - Product Description 24
Table 30: Concept Medical Inc - Ongoing Clinical Trials Overview 25
Table 31: Magic Touch - Assessment of the Novel MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions 26
Table 32: Magic Touch - First-in-man Assessment of the Novel Magictouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions 26
Table 33: Eurocor GmbH Pipeline Products and Ongoing Clinical Trials Overview 27
Table 34: DIOR Paclitaxel-Eluting Coronary Balloon Catheter - Product Status 28
Table 35: DIOR Paclitaxel-Eluting Coronary Balloon Catheter - Product Description 28
Table 36: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products and Ongoing Clinical Trials Overview 29
Table 37: PTCA Drug Eluting Balloon - Product Status 29
Table 38: PTCA Drug Eluting Balloon - Product Description 29
Table 39: Maxcor Inc. Pipeline Products and Ongoing Clinical Trials Overview 30
Table 40: Next Generation Rapamycin (Sirolimus)-Based DEB - Product Status 30
Table 41: Next Generation Rapamycin (Sirolimus)-Based DEB - Product Description 30
Table 42: Micell Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 31
Table 43: Drug-Coated Balloon - Product Status 32
Table 44: Drug-Coated Balloon - Product Description 32
Table 45: QualiMed Innovative Medizinprodukte GmbH Pipeline Products and Ongoing Clinical Trials Overview 33
Table 46: Kinesyx Next Generation Drug Coated Balloon - Product Status 34
Table 47: Kinesyx Next Generation Drug Coated Balloon - Product Description 34
Table 48: The Spectranetics Corporation Pipeline Products and Ongoing Clinical Trials Overview 35
Table 49: Drug Coated AngioSculpt Balloon - Product Status 36
Table 50: Drug Coated AngioSculpt Balloon - Product Description 36
Table 51: Vascular Nanotransfer Technologies Pipeline Products and Ongoing Clinical Trials Overview 37
Table 52: Mitomycin-Based DCB - Coronary - Product Status 37
Table 53: Mitomycin-Based DCB - Coronary - Product Description 37
Table 54: Paclitaxel-Based DCB - Coronary - Product Status 38
Table 55: Paclitaxel-Based DCB - Coronary - Product Description 38
Table 56: Glossary 46

1.2 List of Figures
Figure 1: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 6
Figure 2: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Territory 7
Figure 3: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 8
Figure 4: PTCA Coronary Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 9
Figure 5: PTCA Coronary Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 10

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Denmark Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

Denmark Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

  • $ 5995
  • Industry report
  • September 2016
  • by Global Data

Denmark Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others Summary ...

Greece Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

Greece Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

  • $ 5995
  • Industry report
  • September 2016
  • by Global Data

Greece Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others Summary GlobalData’s ...

Ireland Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

Ireland Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

  • $ 5995
  • Industry report
  • September 2016
  • by Global Data

Ireland Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others Summary ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.